{
    "nct_id": "NCT05972720",
    "official_title": "An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Firi-cel, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma After CD19-directed CAR T-cell Therapy",
    "inclusion_criteria": "* Aged â‰¥18 years\n* Relapsed or refractory, histologically confirmed large B-cell lymphoma.\n* Must have relapsed or refractory diseae after last therapy.\n* For enrollment in cohort 1, patients must have previously received a CD19-directed CAR T-cell therapy\n* For enrollment in cohort 3, patients must have received at least two prior lines of therapy including a bispecific T-cel engaging antibody therapy.\n* Must have at least one radiographically measurable lesion.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate hematological, renal, and liver function\n* Willing and able to remain within 1 hour of the treating center for at least 4 weeks after infusion.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Clinically significant concurrent medical illness\n* Active fungal, bacterial, viral or other infection.\n* Prior allogeneic stem cell transplant or allogeneic cell therapy\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}